NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Forecast, Price & News $3.78 +0.13 (+3.56%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$3.63▼$3.8650-Day Range$2.92▼$7.4852-Week Range$2.55▼$9.65Volume963,018 shsAverage Volume2.88 million shsMarket Capitalization$361.25 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ARS Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside217.5% Upside$12.00 Price TargetShort InterestBearish14.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.60Based on 17 Articles This WeekInsider TradingAcquiring Shares$31.43 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.71) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.96 out of 5 starsMedical Sector667th out of 972 stocksPharmaceutical Preparations Industry313th out of 449 stocks 3.1 Analyst's Opinion Consensus RatingARS Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, ARS Pharmaceuticals has a forecasted upside of 217.5% from its current price of $3.78.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.19% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 7.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SPRY. Previous Next 3.1 News and Social Media Coverage News SentimentARS Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for ARS Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest23 people have searched for SPRY on MarketBeat in the last 30 days. MarketBeat Follows16 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 433% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have bought 1,924.78% more of their company's stock than they have sold. Specifically, they have bought $31,431,000.00 in company stock and sold $1,552,313.00 in company stock.Percentage Held by Insiders35.60% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.41% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ARS Pharmaceuticals are expected to decrease in the coming year, from ($0.71) to ($0.87) per share.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ARS Pharmaceuticals (NASDAQ:SPRY) StockARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for patients and parents affected by severe allergic reactions. It is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for patients and their caregivers with type I allergic reactions, including anaphylaxis. The company was founded in 2015 and is based in San Diego, California.Read More SPRY Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SPRY Stock News HeadlinesSeptember 29, 2023 | finance.yahoo.comARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist InvestorsSeptember 29, 2023 | finance.yahoo.com3 Small Biotech Stocks That Could Be StarsOctober 1, 2023 | Stansberry Research (Ad)Experts: "NVIDIA Bubble" Could Affect Entire MarketSeveral major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.September 28, 2023 | finance.yahoo.comWe're Hopeful That ARS Pharmaceuticals (NASDAQ:SPRY) Will Use Its Cash WiselySeptember 26, 2023 | benzinga.comFisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On TuesdaySeptember 26, 2023 | benzinga.comDirector At This Health Care Company Buys $8.18M of StockSeptember 26, 2023 | americanbankingnews.comARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Ra Capital Management, L.P. Buys 2,700,000 Shares of StockSeptember 25, 2023 | americanbankingnews.comLeerink Partnrs Comments on ARS Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:SPRY)October 1, 2023 | Stansberry Research (Ad)Experts: "NVIDIA Bubble" Could Affect Entire MarketSeveral major analysts are warning that NVIDIA and other tech giants may have gotten “too big to succeed”.September 25, 2023 | americanbankingnews.comFY2023 Earnings Estimate for ARS Pharmaceuticals, Inc. Issued By Wedbush (NASDAQ:SPRY)September 23, 2023 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at SVB LeerinkSeptember 23, 2023 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Given New $5.00 Price Target at WedbushSeptember 23, 2023 | americanbankingnews.comResearch Analysts Set Expectations for ARS Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:SPRY)September 23, 2023 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at Leerink PartnrsSeptember 22, 2023 | msn.comARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing ViewsSeptember 22, 2023 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Rating Lowered to Market Perform at William BlairSeptember 21, 2023 | markets.businessinsider.comWhat's Going On With ARS Pharmaceuticals Stock Today?September 21, 2023 | finance.yahoo.comARS Pharmaceuticals (SPRY) Down on CRL for Nasal SpraySeptember 21, 2023 | msn.comARS Pharma (NASDAQ:SPRY) Plummets on FDA Snub for Epinephrine Nasal SpraySeptember 21, 2023 | finance.yahoo.comFed’s Message Is Louder Than Its Rate Call. Why That’s Critical for Investors.September 20, 2023 | msn.comFDA Declines to Approve Epinephrine Nasal-Spray, Asks for Additional DataSeptember 20, 2023 | msn.comARS Pharma shares plummet after FDA asks for extra test of nasal spraySeptember 20, 2023 | marketwatch.comARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback >SPRYSeptember 20, 2023 | msn.comARS Pharma hits 52-week low as William Blair downgrades on FDA snubSeptember 20, 2023 | msn.comBiggest stock movers today: Instacart, ARS Pharmaceuticals and moreSeptember 20, 2023 | marketwatch.comARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray >SPRYSeptember 20, 2023 | markets.businessinsider.comARS Pharma : FDA Issues CRL For Nasal Spray NDA With Request For Addl Study; Stock DownSee More Headlines Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRY CUSIPN/A CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.00 High Stock Price Forecast$17.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+217.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,680,000.00 Net MarginsN/A Pretax Margin-24,357.53% Return on Equity-20.33% Return on Assets-19.71% Debt Debt-to-Equity RatioN/A Current Ratio25.37 Quick Ratio25.37 Sales & Book Value Annual Sales$219,000.00 Price / Sales1,649.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.90 per share Price / Book1.30Miscellaneous Outstanding Shares95,568,000Free Float61,546,000Market Cap$361.25 million OptionableOptionable Beta-0.12 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Richard Lowenthal M.B.A. (Age 57)M.S., MSMSEL, Founder, Pres, CEO & Director Comp: $908.83kDr. Sarina Tanimoto M.B.A. (Age 55)M.D., Co-Founder & Chief Medical Officer Comp: $748.97kMr. Eric Karas (Age 51)Chief Commercial Officer Comp: $618.61kDr. Robert Bell Ph.D.Co-Founder & Chief Science OfficerMs. Kathleen D. Scott CPAChief Financial OfficerMr. Brian T. Dorsey M.S. (Age 55)Chief Operations Officer Mr. Alexander A. Fitzpatrick Esq. (Age 56)Chief Legal Officer & Sec. Mr. Daniel RelovskySr. VP of MarketingMr. Harris Kaplan M.B.A. (Age 71)MBA, Exec. VP of Commercial Strategy Mr. Justin Chakma (Age 33)Chief Bus. Officer & Sec. More ExecutivesKey CompetitorsPrecigenNASDAQ:PGENCOMPASS PathwaysNASDAQ:CMPSArcutis BiotherapeuticsNASDAQ:ARQTSIGA TechnologiesNASDAQ:SIGAAldeyra TherapeuticsNASDAQ:ALDXView All CompetitorsInsiders & InstitutionsRa Capital Management, L.P.Bought 2,700,000 shares on 9/21/2023Total: $8.18 M ($3.03/share)Barclays PLCBought 20,460 shares on 9/21/2023Ownership: 0.021%Laura ShawverSold 100,000 sharesTotal: $771,000.00 ($7.71/share)Ra Capital Management, L.P.Bought 3,750,000 shares on 8/29/2023Total: $23.25 M ($6.20/share)California State Teachers Retirement SystemBought 41,282 shares on 8/21/2023Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions SPRY Stock - Frequently Asked Questions Should I buy or sell ARS Pharmaceuticals stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SPRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPRY, but not buy additional shares or sell existing shares. View SPRY analyst ratings or view top-rated stocks. What is ARS Pharmaceuticals' stock price forecast for 2023? 4 Wall Street research analysts have issued 12 month price targets for ARS Pharmaceuticals' shares. Their SPRY share price forecasts range from $5.00 to $17.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 217.5% from the stock's current price. View analysts price targets for SPRY or view top-rated stocks among Wall Street analysts. How have SPRY shares performed in 2023? ARS Pharmaceuticals' stock was trading at $8.53 on January 1st, 2023. Since then, SPRY shares have decreased by 55.7% and is now trading at $3.78. View the best growth stocks for 2023 here. When is ARS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our SPRY earnings forecast. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business earned $0.01 million during the quarter. What is ARS Pharmaceuticals' stock symbol? ARS Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPRY." How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ARS Pharmaceuticals' stock price today? One share of SPRY stock can currently be purchased for approximately $3.78. How much money does ARS Pharmaceuticals make? ARS Pharmaceuticals (NASDAQ:SPRY) has a market capitalization of $361.25 million and generates $219,000.00 in revenue each year. How can I contact ARS Pharmaceuticals? ARS Pharmaceuticals' mailing address is 500 Fairview Ave N Suite 600, Seattle WA, 98109. The official website for the company is ars-pharma.com. The company can be reached via phone at 206-456-2900 or via email at ir@silverbacktx.com. This page (NASDAQ:SPRY) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.